Aydın Ali Özüer, Ph.D., has over 25 years of international experience in biotechnology, cell and gene therapies, and cGMP manufacturing. He graduated from Middle East Technical University with a degree in Chemical Engineering and completed his graduate and doctoral studies in Chemical Engineering at the University of Pittsburgh. He also completed graduate studies in Strategy and Operations Management and Clinical Research.

He began his career as a Process Engineer at SEKA and later held senior roles in process development, technology transfer, global manufacturing services, and cell and gene therapies at the University of Pittsburgh and various pharmaceutical companies in the United States.

Throughout his career, Özüer has taken on responsibilities across the full lifecycle from early-stage development to regulatory processes and commercialization, contributing to key projects in biotechnology and advanced therapies. He played a leadership role in the team that achieved FDA and EMA clinical trial approvals for Turkey’s first national biosimilar monoclonal antibody and also held leadership responsibility in the CMC submission process of KYMRIAH, the first FDA-approved gene therapy (CAR T-cell therapy) in the United States.

Since August 2021, he has been serving as President, AbdiBio, where he leads the company’s biotechnology strategy and drives innovation-led growth.